Please assess the completion status of the following clinical trial:

Trial Title: Addressing Involuntary Movements in Tardive Dyskinesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* History of using a dopamine receptor antagonist for at least 3 months~* Clinical diagnosis of tardive dyskinesia and has had symptoms for at least 3 months prior to screening~* Subjects with underlying psychiatric diagnosis are stable and have no change in psychoactive medications~* Have a mental health provider and does not anticipate any changes to treatment regimen in the next 3 months~* History of being compliant with prescribed medications~* Able to swallow study drug whole~* Be in good general health and is expected to attend all study visits and complete study assessments~* Female subjects must not be pregnant and must agree to an acceptable method of contraception throughout the study~Exclusion Criteria:~* Currently receiving medication for the treatment of tardive dyskinesia~* Have a neurological condition other than tardive dyskinesia that may interfere with assessing the severity of dyskinesias~* Have a serious untreated or undertreated psychiatric illness~* Have recent history or presence of violent behavior~* Have unstable or serious medical illness~* Have evidence of hepatic impairment~* Have evidence of renal impairment~* Have known allergy to any component of SD-809 or tetrabenazine~* Has participated in an investigational drug or device trial and received study drug or device within 30 days~* Have acknowledged use of illicit drugs~* Have a history of alcohol or substance abuse in the previous 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablets taken twice daily for 12 weeks.
- SD-809 12 mg/day (Type: EXPERIMENTAL): SD-809 tablets 6 mg taken twice a day (BID) for 12 weeks.
- SD-809 24 mg/day (Type: EXPERIMENTAL): SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 12 mg BID. The total daily dose of 24 mg was maintained for an additional 8 weeks.
- SD-809 36 mg/day (Type: EXPERIMENTAL): SD-809 tablets dose starting at 6 mg twice a day (BID) and titrated over 4 weeks to 18 mg BID. The total daily dose of 36 mg was maintained for an additional 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).